MarketPulse

immunocompromised patients

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aicuris Wins FDA Priority Review for First HSV Treatment in 20+ Years

Aicuris receives FDA Priority Review for pritelivir, a novel herpes simplex virus treatment. Phase 3 data shows 82.4% healing rate; PDUFA decision expected Q4 2026.
AHKSYPhase 3 trialPDUFA
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Atea's AT-587 Shows Promise as Potential First HEV Treatment in Preclinical Study

Atea's AT-587 shows promise as first potential HEV treatment, demonstrating 30-150x greater antiviral activity than existing agents in preclinical studies. Phase 1 trials expected mid-2026.
AVIRPhase 1 clinical trialHepatitis E Virus